<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03660787</url>
  </required_header>
  <id_info>
    <org_study_id>SG-2/1215</org_study_id>
    <nct_id>NCT03660787</nct_id>
  </id_info>
  <brief_title>Efficacy and Dose Ranging Study of Seroguard</brief_title>
  <official_title>Phase II Multi-center Randomized Double-blind Placebo-controlled Efficacy and Dose Ranging Trial of the Drug Product Seroguard, Solution (JSC Pharmasyntez, Russia) Used for the Prevention of Pelvic Adhesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmasyntez</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cromos Pharma, LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pharmasyntez</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial was a multi-center, double-blind, randomized, parallel group, placebo-controlled,
      phase II study in adult hospitalized female patients with the confirmed diagnosis of pelvic
      adhesive disease in Study centres in Russia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In order to evaluate efficacy and safety of Seroguard, solution for IP administration, a
      study design meeting the set objectives was selected: prospective, multi-center,
      double-blind, randomized, parallel group, placebo-controlled study.

      Given the fact that comparison with placebo is considered the best way to prove efficacy and
      safety of a drug and that currently there are no drugs with a similar mechanism of action at
      the pharmaceutical product market, a placebo-controlled, parallel group study design was
      selected.

      A randomized, parallel group study design was chosen in order to ensure minimization of a
      selection bias.

      Subjects were randomized into four groups (two groups of the test drug and two placebo groups
      corresponding to the two doses) to enable a comparison of Seroguard administration at two
      doses.

      A double-blind study design was selected in order to ensure minimization of an outcome
      evaluation bias.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 4, 2017</start_date>
  <completion_date type="Actual">January 23, 2018</completion_date>
  <primary_completion_date type="Actual">January 23, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>The present study was conducted as a double blind trial. Neither a medical investigator, nor patients had access to the treatment assignment code in order to ensure the maximum objective evaluation of the primary endpoint.
Blinding was performed in such a way that disclosing a randomization code of a certain subject excluded a disclosure of the code in general (i.e. the randomization code had no indication to the treatment group). However, there were no cases of the randomization code disclosure in the study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Reduction of Adhesions Number by 3 or More</measure>
    <time_frame>30±4 days after surgical intervention</time_frame>
    <description>The number of adhesions according to the first MRI data was compared to the number according to the data of second MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Thickness of Pelvic Adhesions</measure>
    <time_frame>30±4 days after surgery</time_frame>
    <description>The change from baseline was defined. It was evaluated by comparing baseline MRI data and repeated MRI data. Results were estimated according to scale from 0 to 3 where 0 - no adhesions, 1 - thin (filmy or filiform), 2 - marked, 3 - marked with an impaired passage through organs involved.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Detection of Pelvic Organs Limited Mobility</measure>
    <time_frame>30±4 days after surgery</time_frame>
    <description>The frequency was estimated based on transvaginal ultrasound results</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Detection of Hyperechoic Linear Lesions Post Surgery</measure>
    <time_frame>30±4 days after surgery</time_frame>
    <description>The frequency was estimated based on transvaginal ultrasound results</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Number of Participants in Detecting Pelvic Organs Limited Mobility</measure>
    <time_frame>30±4 days after surgery</time_frame>
    <description>Absolute change of count of participants was measured with detecting pelvic organs limited mobility from the baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change Number of Participants in Detecting Hyperechoic Linear Lesions</measure>
    <time_frame>30±4 days after surgery</time_frame>
    <description>Frequency of detecting after repeated transvaginal ultrasound results was compared to baseline indications (4 or more)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Detection of no Ultrasound Signs of Pelvic Adhesive Disease Post Surgery</measure>
    <time_frame>30±4 days after surgery</time_frame>
    <description>No limited mobility of pelvic organs and no hyperechoic linear lesions should be shown</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">114</enrollment>
  <condition>Adhesion</condition>
  <arm_group>
    <arm_group_label>Placebo, 1.5 mL/kg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>each subject received the placebo at the dose of 1.5 mL/kg of body weight;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, 2.4 mL/kg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>each subject received the placebo at the dose of 2.4 mL/kg of body weight;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Seroguard, 1.5 mL/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>each subject received the test drug at the dose of 1.5 mL/kg of body weight;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Seroguard, 2.4 mL/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>each subject received the test drug at the dose of 2.4 mL/kg of body weight.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Seroguard</intervention_name>
    <description>Seroguard 0.41 g/L solution</description>
    <arm_group_label>Seroguard, 1.5 mL/kg</arm_group_label>
    <arm_group_label>Seroguard, 2.4 mL/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline</description>
    <arm_group_label>Placebo, 1.5 mL/kg</arm_group_label>
    <arm_group_label>Placebo, 2.4 mL/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female patients aged from 18 to 45 years with the confirmed diagnosis of pelvic
             adhesions having indications for surgery (laparoscopic adhesiolysis).

          2. Voluntarily and personally signed and dated Form of Informed Consent.

          3. Female patients with pelvic adhesions confirmed by gynecological and ultrasound
             examination.

        Exclusion Criteria:

          1. Female patients having contraindications to surgical treatment (including acute or
             exacerbated chronical adnexal inflammation);

          2. Body mass index of 30.0 kg/m2 and more;

          3. Known hypersensitivity to the test drug components (Seroguard);

          4. Pregnancy, breastfeeding or planning a pregnancy during the clinical trial;

          5. Refusal to use effective contraception methods throughout the study;

          6. Positive HIV, RW, HBV or HCV test result;

          7. Alcohol abuse, drug addiction, and toxicomania (except smoking);

          8. American Society of Anesthesiologists physical status category III and more (ASA);

          9. Purulent process in the abdominal cavity;

         10. Disseminated endometriosis;

         11. WBC count more than 10*109/L at the complete blood count;

         12. Need of using any drugs during the surgery other than 0.02% chlorhexidine aqueous
             solution throughout the surgery, as well as the test drug or the placebo (0.9% sodium
             chloride) administered intraperitoneally in the end of surgery.

         13. Concomitant diseases that may require conversion of the surgical intervention by other
             indications;

         14. Type I or II diabetes mellitus;

         15. Deep vein thrombosis and/or PATE at the screening or in the medical history;

         16. Renal impairment (glomerular filtration rate less than 60 mL/min/1.73 m2 assessed by
             the CKD-EPI equation);

         17. Liver disorders defined as more than 2-fold rise of the upper limit of normal of one
             of the following enzymes: ALT, AST, GGTP, AP, or more than 2-fold total bilirubin
             increase;

         18. Myocardial infarction within 6 months before screening;

         19. Any concomitant diseases accompanied by heart failure;

         20. Clinically significant ECG changes (as to the investigator's opinion);

         21. Any concomitant diseases accompanied by respiratory failure;

         22. Any oncological disease within 3 years before enrollment into the study;

         23. Systemic inflammatory diseases;

         24. Diseases associated with chronic hemorrhages;

         25. Blood diseases (anemias of any origin, hemoglobinopathies, inherited and acquired
             coagulopathies, hemostasis disorders, thrombocytopenias, and thrombocytopathias, any
             hemoblastoses);

         26. Any other disease that, in the investigator's opinion, may affect study results or
             present an additional threat to well-being of a patient after administration of the
             study drug;

         27. Use of anticoagulants, antiaggregants (except for acetylsalicylic acid at the dose of
             less than 325 mg/day) at the moment of inclusion into the study or planning to do so
             during the study;

         28. Use of drugs with pronounced hemato-, hepato-, or nephrotoxic action, drugs of
             biological origin;

         29. Need to administer cytostatics, systemic glucocorticosteroids, and other
             immunosuppressive agents during the patient's participation in the study.

         30. Participation in any other clinical trial within 30 days before screening;

         31. Contraindications to MRI (presence of implants or implanted electronic devices);

         32. Impossibility or inability to comply with the requirements of the protocol, including
             for physical, psychic or social reasons, in the investigator's opinion.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mikhail Shurygin, PhD,D.M.Sc.</last_name>
    <role>Study Chair</role>
    <affiliation>Pharmasyntez</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Krai Government-Owned State Funded Healthcare Institution &quot;Krai Clinical Hospital&quot;</name>
      <address>
        <city>Krasnoyarsk</city>
        <state>Krasnoyarsk Krai</state>
        <zip>660022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Educational Government-Financed Institution of Higher Professional Education &quot;Krasnoyarsk State Medical University named after Prof. V.F. Voino-Yasenetsky&quot; of the Ministry of Healthcare of the Russian Federation at the clinical site Publicly Funded</name>
      <address>
        <city>Krasnoyarsk</city>
        <state>Krasnoyarsk Krai</state>
        <zip>660074</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Funded Healthcare Institution of Moscow of City Health Department &quot;V.M. Buyanov Municipal Clinical Hospital&quot;</name>
      <address>
        <city>Moscow</city>
        <state>Moscow Region</state>
        <zip>115516</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Institution &quot;V.I. Kulakov Research Center for Obstetrics, Gynecology, and Perinatology&quot; of the Ministry of Healthcare and Social Development of the Russian Federation.</name>
      <address>
        <city>Moscow</city>
        <state>Moscow Region</state>
        <zip>117997</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Educational Government-Financed Institution of Higher Professional Education &quot;Kazan State Medical University&quot; of the Ministry of Health of the Russian at the clinical site of Kazan Maternity Hospital No. 3 named after V.S. Gruzdev</name>
      <address>
        <city>Kazan</city>
        <state>Republic Of Tatarstan</state>
        <zip>420012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Funded Health Care Institution &quot;Bryansk Municipal Hospital No 1</name>
      <address>
        <city>Bryansk</city>
        <state>The Bryansk Region</state>
        <zip>241035</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Educational Government-Financed Institution of Higher Education &quot;Kemerovo State Medical University&quot; of the Ministry of Healthcare of the Russian Federation at the clinical site of Kemerovo Oblast Publicly Funded Healthcare Institution &quot;L.A.</name>
      <address>
        <city>Kemerovo</city>
        <state>The Kemerovo Region</state>
        <zip>650000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Funded Healthcare Institution &quot;L.G. Sokolov Federal Biomedical Agency Clinical Hospital No 122&quot;.</name>
      <address>
        <city>Saint Petersburg</city>
        <state>The Leningrad Region</state>
        <zip>194291</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Funded Scientific Institution &quot;Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott&quot; of the Ministry of Healthcare of the Russian Federation</name>
      <address>
        <city>Saint Petersburg</city>
        <state>The Leningrad Region</state>
        <zip>199034</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow Oblast State Funded Healthcare Institution &quot;Moscow Oblast Research Institute of Obstetrics and Gynecology&quot;</name>
      <address>
        <city>Moscow</city>
        <state>The Moscow Region</state>
        <zip>101000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Funded Healthcare Institution of Moscow of City Health Department &quot;Moscow Municipal Clinical Hospital No 31&quot;</name>
      <address>
        <city>Moscow</city>
        <state>The Moscow Region</state>
        <zip>119415</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Educational Government-Financed Institution of Higher Professional Education &quot;Rostov State Medical University&quot; of the Ministry of Healthcare of the Russian Federation at the clinical site of Obstetrics and Pediatrics Research Institute</name>
      <address>
        <city>Rostov-on-Don</city>
        <state>The Rostov Region</state>
        <zip>344013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Educational Government-Financed Institution of Higher Education &quot;I.P. Pavlov Ryazan State Medical University&quot; of the Ministry of Healthcare of the Russian Federation at the clinical site of State Funded Healthcare Institution &quot;Municipal Clin</name>
      <address>
        <city>Ryazan'</city>
        <state>The Ryazan Region</state>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Funded Healthcare Institution &quot;Ural Research Institute of Maternal and Infant Care&quot; of the Ministry of Healthcare of the Russian Federation</name>
      <address>
        <city>Yekaterinburg</city>
        <state>The Sverdlovsk Region</state>
        <zip>620028</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <reference>
    <citation>Miller JH, Weinberg RK, Canino NL, Klein NA, Soules MR. The pattern of infertility diagnoses in women of advanced reproductive age. Am J Obstet Gynecol. 1999 Oct;181(4):952-7.</citation>
    <PMID>10521760</PMID>
  </reference>
  <reference>
    <citation>Dun EC, Nezhat CH. Tubal factor infertility: diagnosis and management in the era of assisted reproductive technology. Obstet Gynecol Clin North Am. 2012 Dec;39(4):551-66. doi: 10.1016/j.ogc.2012.09.006. Review.</citation>
    <PMID>23182560</PMID>
  </reference>
  <reference>
    <citation>Weström L. Effect of acute pelvic inflammatory disease on fertility. Am J Obstet Gynecol. 1975 Mar 1;121(5):707-13.</citation>
    <PMID>123123</PMID>
  </reference>
  <reference>
    <citation>Weström LV. Sexually transmitted diseases and infertility. Sex Transm Dis. 1994 Mar-Apr;21(2 Suppl):S32-7. Review.</citation>
    <PMID>8042113</PMID>
  </reference>
  <reference>
    <citation>Patil M. Assessing tubal damage. J Hum Reprod Sci. 2009 Jan;2(1):2-11. doi: 10.4103/0974-1208.51335.</citation>
    <PMID>19562067</PMID>
  </reference>
  <reference>
    <citation>Sutherland AM. The changing pattern of tuberculosis of the female genital tract. A thirty year survey. Arch Gynecol. 1983;234(2):95-101.</citation>
    <PMID>6667046</PMID>
  </reference>
  <reference>
    <citation>Mueller BA, Daling JR, Moore DE, Weiss NS, Spadoni LR, Stadel BV, Soules MR. Appendectomy and the risk of tubal infertility. N Engl J Med. 1986 Dec 11;315(24):1506-8.</citation>
    <PMID>3785307</PMID>
  </reference>
  <reference>
    <citation>Schwartz L, Diamond M. Formation, Reduction, and Treatment of Adhesive Disease. Seminars in Reproductive Medicine. 1991; 9(02): p. 89-99.</citation>
  </reference>
  <reference>
    <citation>Vaid K, Mehra S, Verma M, Jain S, Sharma A, Bhaskaran S. Pan endoscopic approach &quot;hysterolaparoscopy&quot; as an initial procedure in selected infertile women. J Clin Diagn Res. 2014 Feb;8(2):95-8. doi: 10.7860/JCDR/2014/7271.4018. Epub 2014 Feb 3.</citation>
    <PMID>24701493</PMID>
  </reference>
  <reference>
    <citation>Neerja, Jain K. Role of laporoscopy-hysteroscopy in cases of infertility with pregnancy outcome. J Indian Med Assoc. 2014 Feb;112(2):85-6, 88.</citation>
    <PMID>25935960</PMID>
  </reference>
  <reference>
    <citation>Diamond MP, Daniell JF, Feste J, Surrey MW, McLaughlin DS, Friedman S, Vaughn WK, Martin DC. Adhesion reformation and de novo adhesion formation after reproductive pelvic surgery. Fertil Steril. 1987 May;47(5):864-6.</citation>
    <PMID>2952528</PMID>
  </reference>
  <reference>
    <citation>DeCherney AH, Mezer HC. The nature of posttuboplasty pelvic adhesions as determined by early and late laparoscopy. Fertil Steril. 1984 Apr;41(4):643-6.</citation>
    <PMID>6231195</PMID>
  </reference>
  <reference>
    <citation>Al-Jabri S, Tulandi T. Management and prevention of pelvic adhesions. Semin Reprod Med. 2011 Mar;29(2):130-7. doi: 10.1055/s-0031-1272475. Epub 2011 Mar 24. Review.</citation>
    <PMID>21437827</PMID>
  </reference>
  <reference>
    <citation>Brochhausen C, Schmitt VH, Planck CN, Rajab TK, Hollemann D, Tapprich C, Krämer B, Wallwiener C, Hierlemann H, Zehbe R, Planck H, Kirkpatrick CJ. Current strategies and future perspectives for intraperitoneal adhesion prevention. J Gastrointest Surg. 2012 Jun;16(6):1256-74. doi: 10.1007/s11605-011-1819-9. Review.</citation>
    <PMID>22297658</PMID>
  </reference>
  <reference>
    <citation>Coulthard LR, White DE, Jones DL, McDermott MF, Burchill SA. p38(MAPK): stress responses from molecular mechanisms to therapeutics. Trends Mol Med. 2009 Aug;15(8):369-79. doi: 10.1016/j.molmed.2009.06.005. Epub 2009 Aug 6. Review.</citation>
    <PMID>19665431</PMID>
  </reference>
  <reference>
    <citation>Ward BC, Kavalukas S, Brugnano J, Barbul A, Panitch A. Peptide inhibitors of MK2 show promise for inhibition of abdominal adhesions. J Surg Res. 2011 Jul;169(1):e27-36. doi: 10.1016/j.jss.2011.01.043. Epub 2011 Feb 23.</citation>
    <PMID>21492875</PMID>
  </reference>
  <reference>
    <citation>Katada J, Saito H, Ohashi A. Significance of cyclooxygenase-2 induced via p38 mitogen-activated protein kinase in mechanical stimulus-induced peritoneal adhesion in mice. J Pharmacol Exp Ther. 2005 Apr;313(1):286-92. Epub 2004 Dec 2.</citation>
    <PMID>15576468</PMID>
  </reference>
  <reference>
    <citation>U.S. Food and Drug Administration. U.S. Food and Drug Administration. [Online]. Northborough; 2006 [cited 2015 Dec 22. Available from: http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4217b1_01_Executive%20Summary.pdf.</citation>
  </reference>
  <reference>
    <citation>Ghonge NP, Ghonge SD. Computed tomography and magnetic resonance imaging in the evaluation of pelvic peritoneal adhesions: What radiologists need to know? Indian J Radiol Imaging. 2014 Apr;24(2):149-55. doi: 10.4103/0971-3026.134400.</citation>
    <PMID>25024524</PMID>
  </reference>
  <reference>
    <citation>diZerega GS. The peritoneum and its response to surgical injury. Prog Clin Biol Res. 1990;358:1-11.</citation>
    <PMID>2217485</PMID>
  </reference>
  <reference>
    <citation>diZerega GS, Campeau JD. Peritoneal repair and post-surgical adhesion formation. Hum Reprod Update. 2001 Nov-Dec;7(6):547-55. Review.</citation>
    <PMID>11727863</PMID>
  </reference>
  <reference>
    <citation>Lali FV, Hunt AE, Turner SJ, Foxwell BM. The pyridinyl imidazole inhibitor SB203580 blocks phosphoinositide-dependent protein kinase activity, protein kinase B phosphorylation, and retinoblastoma hyperphosphorylation in interleukin-2-stimulated T cells independently of p38 mitogen-activated protein kinase. J Biol Chem. 2000 Mar 10;275(10):7395-402.</citation>
    <PMID>10702313</PMID>
  </reference>
  <reference>
    <citation>Kumar B, Koul S, Petersen J, Khandrika L, Hwa JS, Meacham RB, Wilson S, Koul HK. p38 mitogen-activated protein kinase-driven MAPKAPK2 regulates invasion of bladder cancer by modulation of MMP-2 and MMP-9 activity. Cancer Res. 2010 Jan 15;70(2):832-41. doi: 10.1158/0008-5472.CAN-09-2918. Epub 2010 Jan 12.</citation>
    <PMID>20068172</PMID>
  </reference>
  <reference>
    <citation>Louizos AA, Hadzilia SJ, Leandros E, Kouroukli IK, Georgiou LG, Bramis JP. Postoperative pain relief after laparoscopic cholecystectomy: a placebo-controlled double-blind randomized trial of preincisional infiltration and intraperitoneal instillation of levobupivacaine 0.25%. Surg Endosc. 2005 Nov;19(11):1503-6. Epub 2005 Oct 3.</citation>
    <PMID>16328673</PMID>
  </reference>
  <reference>
    <citation>Innes A, Burden RP, Finch RG, Morgan AG. Treatment of resistant peritonitis in continuous ambulatory peritoneal dialysis with intraperitoneal urokinase: a double-blind clinical trial. Nephrol Dial Transplant. 1994;9(7):797-9.</citation>
    <PMID>7970121</PMID>
  </reference>
  <reference>
    <citation>Szem JW, Hydo L, Barie PS. A double-blinded evaluation of intraperitoneal bupivacaine vs saline for the reduction of postoperative pain and nausea after laparoscopic cholecystectomy. Surg Endosc. 1996 Jan;10(1):44-8.</citation>
    <PMID>8711605</PMID>
  </reference>
  <reference>
    <citation>Labaille T, Mazoit JX, Paqueron X, Franco D, Benhamou D. The clinical efficacy and pharmacokinetics of intraperitoneal ropivacaine for laparoscopic cholecystectomy. Anesth Analg. 2002 Jan;94(1):100-5, table of contents.</citation>
    <PMID>11772809</PMID>
  </reference>
  <reference>
    <citation>Ahmad G, Mackie FL, Iles DA, O'Flynn H, Dias S, Metwally M, Watson A. Fluid and pharmacological agents for adhesion prevention after gynaecological surgery. Cochrane Database Syst Rev. 2014 Jul 9;(7):CD001298. doi: 10.1002/14651858.CD001298.pub4. Review.</citation>
    <PMID>25005450</PMID>
  </reference>
  <reference>
    <citation>U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Non-Inferiority Clinical Trials.; 2010 [cited 2015 Dec. Available from: http://www.fda.gov/downloads/Drugs/./Guidances/UCM202140.pdf.</citation>
  </reference>
  <reference>
    <citation>Chow S, Shao J, Wang H. Sample Size Calculations in Clinical Research. 2nd ed.: Chapman&amp;Hall / CRC Biostatistics Series; 2008.</citation>
  </reference>
  <reference>
    <citation>Guerriero S, Ajossa S, Lai MP, Mais V, Paoletti AM, Melis GB. Transvaginal ultrasonography in the diagnosis of pelvic adhesions. Hum Reprod. 1997 Dec;12(12):2649-53.</citation>
    <PMID>9455829</PMID>
  </reference>
  <reference>
    <citation>Guerriero S, Ajossa S, Garau N, Alcazar JL, Mais V, Melis GB. Diagnosis of pelvic adhesions in patients with endometrioma: the role of transvaginal ultrasonography. Fertil Steril. 2010 Jul;94(2):742-6. doi: 10.1016/j.fertnstert.2009.03.035. Epub 2009 Apr 14.</citation>
    <PMID>19368917</PMID>
  </reference>
  <reference>
    <citation>Julious SA. Sample Sizes for Clinical Trials: CRC Press/Taylor &amp; Francis; 2010.</citation>
  </reference>
  <reference>
    <citation>Gnoth C, Godehardt E, Frank-Herrmann P, Friol K, Tigges J, Freundl G. Definition and prevalence of subfertility and infertility. Hum Reprod. 2005 May;20(5):1144-7. Epub 2005 Mar 31. Review.</citation>
    <PMID>15802321</PMID>
  </reference>
  <reference>
    <citation>Gnoth C, Godehardt D, Godehardt E, Frank-Herrmann P, Freundl G. Time to pregnancy: results of the German prospective study and impact on the management of infertility. Hum Reprod. 2003 Sep;18(9):1959-66.</citation>
    <PMID>12923157</PMID>
  </reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>August 31, 2018</study_first_submitted>
  <study_first_submitted_qc>September 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 7, 2018</study_first_posted>
  <results_first_submitted>October 31, 2018</results_first_submitted>
  <results_first_submitted_qc>June 17, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 19, 2019</results_first_posted>
  <last_update_submitted>June 17, 2019</last_update_submitted>
  <last_update_submitted_qc>June 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adhesion</keyword>
  <keyword>Efficacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tissue Adhesions</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 6, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/87/NCT03660787/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 24, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/87/NCT03660787/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>114 is the number of enrolled and screened participants according to the protocol, but during the screening process some people were withdrawn from the study before randomization because some of them did not meet the inclusion criteria and some withdrew the informed consent form themselves. So, the number of randomized participants is 104.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo, 1.5 mL/kg</title>
          <description>each subject received the placebo at the dose of 1.5 mL/kg of body weight;
Placebo: Saline</description>
        </group>
        <group group_id="P2">
          <title>Placebo, 2.4 mL/kg</title>
          <description>each subject received the placebo at the dose of 2.4 mL/kg of body weight;
Placebo: Saline</description>
        </group>
        <group group_id="P3">
          <title>Seroguard, 1.5 mL/kg</title>
          <description>each subject received the test drug at the dose of 1.5 mL/kg of body weight;
Seroguard: Seroguard 0.41 g/L solution</description>
        </group>
        <group group_id="P4">
          <title>Seroguard, 2.4 mL/kg</title>
          <description>each subject received the test drug at the dose of 2.4 mL/kg of body weight.
Seroguard: Seroguard 0.41 g/L solution</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="26"/>
                <participants group_id="P4" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo, 1.5 mL/kg</title>
          <description>each subject received the placebo at the dose of 1.5 mL/kg of body weight;
Placebo: Saline</description>
        </group>
        <group group_id="B2">
          <title>Placebo, 2.4 mL/kg</title>
          <description>each subject received the placebo at the dose of 2.4 mL/kg of body weight;
Placebo: Saline</description>
        </group>
        <group group_id="B3">
          <title>Seroguard, 1.5 mL/kg</title>
          <description>each subject received the test drug at the dose of 1.5 mL/kg of body weight;
Seroguard: Seroguard 0.41 g/L solution</description>
        </group>
        <group group_id="B4">
          <title>Seroguard, 2.4 mL/kg</title>
          <description>each subject received the test drug at the dose of 2.4 mL/kg of body weight.
Seroguard: Seroguard 0.41 g/L solution</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
            <count group_id="B2" value="26"/>
            <count group_id="B3" value="26"/>
            <count group_id="B4" value="26"/>
            <count group_id="B5" value="104"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="104"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.0" spread="6.2"/>
                    <measurement group_id="B2" value="31.6" spread="5.3"/>
                    <measurement group_id="B3" value="31.6" spread="5.4"/>
                    <measurement group_id="B4" value="31.6" spread="5.4"/>
                    <measurement group_id="B5" value="31.5" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="104"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Caucasian race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Russia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Reduction of Adhesions Number by 3 or More</title>
        <description>The number of adhesions according to the first MRI data was compared to the number according to the data of second MRI</description>
        <time_frame>30±4 days after surgical intervention</time_frame>
        <population>7 patients had no results of repeated Pelvic MRI examination that is why the number of Participants is different</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo, 1.5 mL/kg</title>
            <description>each subject received the placebo at the dose of 1.5 mL/kg of body weight;
Placebo: Saline</description>
          </group>
          <group group_id="O2">
            <title>Placebo, 2.4 mL/kg</title>
            <description>each subject received the placebo at the dose of 2.4 mL/kg of body weight;
Placebo: Saline</description>
          </group>
          <group group_id="O3">
            <title>Seroguard, 1.5 mL/kg</title>
            <description>each subject received the test drug at the dose of 1.5 mL/kg of body weight;
Seroguard: Seroguard 0.41 g/L solution</description>
          </group>
          <group group_id="O4">
            <title>Seroguard, 2.4 mL/kg</title>
            <description>each subject received the test drug at the dose of 2.4 mL/kg of body weight.
Seroguard: Seroguard 0.41 g/L solution</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Reduction of Adhesions Number by 3 or More</title>
          <description>The number of adhesions according to the first MRI data was compared to the number according to the data of second MRI</description>
          <population>7 patients had no results of repeated Pelvic MRI examination that is why the number of Participants is different</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Thickness of Pelvic Adhesions</title>
        <description>The change from baseline was defined. It was evaluated by comparing baseline MRI data and repeated MRI data. Results were estimated according to scale from 0 to 3 where 0 - no adhesions, 1 - thin (filmy or filiform), 2 - marked, 3 - marked with an impaired passage through organs involved.</description>
        <time_frame>30±4 days after surgery</time_frame>
        <population>7 patients had no results of repeated Pelvic MRI examination that is why the number of Participants is different</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo, 1.5 mL/kg</title>
            <description>each subject received the placebo at the dose of 1.5 mL/kg of body weight;
Placebo: Saline</description>
          </group>
          <group group_id="O2">
            <title>Placebo, 2.4 mL/kg</title>
            <description>each subject received the placebo at the dose of 2.4 mL/kg of body weight;
Placebo: Saline</description>
          </group>
          <group group_id="O3">
            <title>Seroguard, 1.5 mL/kg</title>
            <description>each subject received the test drug at the dose of 1.5 mL/kg of body weight;
Seroguard: Seroguard 0.41 g/L solution</description>
          </group>
          <group group_id="O4">
            <title>Seroguard, 2.4 mL/kg</title>
            <description>each subject received the test drug at the dose of 2.4 mL/kg of body weight.
Seroguard: Seroguard 0.41 g/L solution</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Thickness of Pelvic Adhesions</title>
          <description>The change from baseline was defined. It was evaluated by comparing baseline MRI data and repeated MRI data. Results were estimated according to scale from 0 to 3 where 0 - no adhesions, 1 - thin (filmy or filiform), 2 - marked, 3 - marked with an impaired passage through organs involved.</description>
          <population>7 patients had no results of repeated Pelvic MRI examination that is why the number of Participants is different</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Detection of Pelvic Organs Limited Mobility</title>
        <description>The frequency was estimated based on transvaginal ultrasound results</description>
        <time_frame>30±4 days after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo, 1.5 mL/kg</title>
            <description>each subject received the placebo at the dose of 1.5 mL/kg of body weight;
Placebo: Saline</description>
          </group>
          <group group_id="O2">
            <title>Placebo, 2.4 mL/kg</title>
            <description>each subject received the placebo at the dose of 2.4 mL/kg of body weight;
Placebo: Saline</description>
          </group>
          <group group_id="O3">
            <title>Seroguard, 1.5 mL/kg</title>
            <description>each subject received the test drug at the dose of 1.5 mL/kg of body weight;
Seroguard: Seroguard 0.41 g/L solution</description>
          </group>
          <group group_id="O4">
            <title>Seroguard, 2.4 mL/kg</title>
            <description>each subject received the test drug at the dose of 2.4 mL/kg of body weight.
Seroguard: Seroguard 0.41 g/L solution</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Detection of Pelvic Organs Limited Mobility</title>
          <description>The frequency was estimated based on transvaginal ultrasound results</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Detection of Hyperechoic Linear Lesions Post Surgery</title>
        <description>The frequency was estimated based on transvaginal ultrasound results</description>
        <time_frame>30±4 days after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo, 1.5 mL/kg</title>
            <description>each subject received the placebo at the dose of 1.5 mL/kg of body weight;
Placebo: Saline</description>
          </group>
          <group group_id="O2">
            <title>Placebo, 2.4 mL/kg</title>
            <description>each subject received the placebo at the dose of 2.4 mL/kg of body weight;
Placebo: Saline</description>
          </group>
          <group group_id="O3">
            <title>Seroguard, 1.5 mL/kg</title>
            <description>each subject received the test drug at the dose of 1.5 mL/kg of body weight;
Seroguard: Seroguard 0.41 g/L solution</description>
          </group>
          <group group_id="O4">
            <title>Seroguard, 2.4 mL/kg</title>
            <description>each subject received the test drug at the dose of 2.4 mL/kg of body weight.
Seroguard: Seroguard 0.41 g/L solution</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Detection of Hyperechoic Linear Lesions Post Surgery</title>
          <description>The frequency was estimated based on transvaginal ultrasound results</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Number of Participants in Detecting Pelvic Organs Limited Mobility</title>
        <description>Absolute change of count of participants was measured with detecting pelvic organs limited mobility from the baseline</description>
        <time_frame>30±4 days after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo, 1.5 mL/kg</title>
            <description>each subject received the placebo at the dose of 1.5 mL/kg of body weight;
Placebo: Saline</description>
          </group>
          <group group_id="O2">
            <title>Placebo, 2.4 mL/kg</title>
            <description>each subject received the placebo at the dose of 2.4 mL/kg of body weight;
Placebo: Saline</description>
          </group>
          <group group_id="O3">
            <title>Seroguard, 1.5 mL/kg</title>
            <description>each subject received the test drug at the dose of 1.5 mL/kg of body weight;
Seroguard: Seroguard 0.41 g/L solution</description>
          </group>
          <group group_id="O4">
            <title>Seroguard, 2.4 mL/kg</title>
            <description>each subject received the test drug at the dose of 2.4 mL/kg of body weight.
Seroguard: Seroguard 0.41 g/L solution</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Number of Participants in Detecting Pelvic Organs Limited Mobility</title>
          <description>Absolute change of count of participants was measured with detecting pelvic organs limited mobility from the baseline</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17"/>
                    <measurement group_id="O2" value="-17"/>
                    <measurement group_id="O3" value="-21"/>
                    <measurement group_id="O4" value="-21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change Number of Participants in Detecting Hyperechoic Linear Lesions</title>
        <description>Frequency of detecting after repeated transvaginal ultrasound results was compared to baseline indications (4 or more)</description>
        <time_frame>30±4 days after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo, 1.5 mL/kg</title>
            <description>each subject received the placebo at the dose of 1.5 mL/kg of body weight;
Placebo: Saline</description>
          </group>
          <group group_id="O2">
            <title>Placebo, 2.4 mL/kg</title>
            <description>each subject received the placebo at the dose of 2.4 mL/kg of body weight;
Placebo: Saline</description>
          </group>
          <group group_id="O3">
            <title>Seroguard, 1.5 mL/kg</title>
            <description>each subject received the test drug at the dose of 1.5 mL/kg of body weight;
Seroguard: Seroguard 0.41 g/L solution</description>
          </group>
          <group group_id="O4">
            <title>Seroguard, 2.4 mL/kg</title>
            <description>each subject received the test drug at the dose of 2.4 mL/kg of body weight.
Seroguard: Seroguard 0.41 g/L solution</description>
          </group>
        </group_list>
        <measure>
          <title>Change Number of Participants in Detecting Hyperechoic Linear Lesions</title>
          <description>Frequency of detecting after repeated transvaginal ultrasound results was compared to baseline indications (4 or more)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17"/>
                    <measurement group_id="O2" value="-16"/>
                    <measurement group_id="O3" value="-19"/>
                    <measurement group_id="O4" value="-18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Detection of no Ultrasound Signs of Pelvic Adhesive Disease Post Surgery</title>
        <description>No limited mobility of pelvic organs and no hyperechoic linear lesions should be shown</description>
        <time_frame>30±4 days after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo, 1.5 mL/kg</title>
            <description>each subject received the placebo at the dose of 1.5 mL/kg of body weight;
Placebo: Saline</description>
          </group>
          <group group_id="O2">
            <title>Placebo, 2.4 mL/kg</title>
            <description>each subject received the placebo at the dose of 2.4 mL/kg of body weight;
Placebo: Saline</description>
          </group>
          <group group_id="O3">
            <title>Seroguard, 1.5 mL/kg</title>
            <description>each subject received the test drug at the dose of 1.5 mL/kg of body weight;
Seroguard: Seroguard 0.41 g/L solution</description>
          </group>
          <group group_id="O4">
            <title>Seroguard, 2.4 mL/kg</title>
            <description>each subject received the test drug at the dose of 2.4 mL/kg of body weight.
Seroguard: Seroguard 0.41 g/L solution</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Detection of no Ultrasound Signs of Pelvic Adhesive Disease Post Surgery</title>
          <description>No limited mobility of pelvic organs and no hyperechoic linear lesions should be shown</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30+-4 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo, 1.5 mL/kg</title>
          <description>each subject received the placebo at the dose of 1.5 mL/kg of body weight;
Placebo: Saline</description>
        </group>
        <group group_id="E2">
          <title>Placebo, 2.4 mL/kg</title>
          <description>each subject received the placebo at the dose of 2.4 mL/kg of body weight;
Placebo: Saline</description>
        </group>
        <group group_id="E3">
          <title>Seroguard, 1.5 mL/kg</title>
          <description>each subject received the test drug at the dose of 1.5 mL/kg of body weight;
Seroguard: Seroguard 0.41 g/L solution</description>
        </group>
        <group group_id="E4">
          <title>Seroguard, 2.4 mL/kg</title>
          <description>each subject received the test drug at the dose of 2.4 mL/kg of body weight.
Seroguard: Seroguard 0.41 g/L solution</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Polymenorrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mikhail Shurygin</name_or_title>
      <organization>Pharmasyntez</organization>
      <phone>+7 3952 550 355 ext 1150</phone>
      <email>m.shurygin@pharmasyntez.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

